Status:

UNKNOWN

TOFAcitinib in SARS-CoV2 Pneumonia

Lead Sponsor:

Università Politecnica delle Marche

Conditions:

SARS-COv2 Related Interstitial Pneumonia

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to SARS-CoV2 infection. Tofacitinib, a JAK1/3-Inhibitor, could mitigate alveolar inflammation by blocking IL-...

Detailed Description

Interstitial Pneumonia is the main complication of SARS-CoV2 infection. Immune system hyperactivation, leading to alveolar inflammation, is the main mechanism in determining lung damage. Evidence are ...

Eligibility Criteria

Inclusion

  • SARS-CoV2 Infection diagnosed by rt-PCR
  • Rx or CT-scan confirmed interstitial pneumonia
  • Hospital admission from less than 24h
  • Written Informed Consent

Exclusion

  • Age \<18 ys or \>65
  • Patients in mechanical ventilation at time of admission
  • Severe Hearth failure (NYHA 3 or 4)
  • Severe History of Chronic Ischemic Hearth Disease, defined as history of Major Adverse Cardiovascular Event and/or recent (one year) revascularization.
  • History of recurrent Deep Venous Thrombosis and Pulmonary Embolism
  • Active Bacterial or Fungal Infection
  • Hematological cancer
  • Metastatic or intractable cancer
  • Pre-existent neurodegenerative disease
  • Severe Hepatic Impairment
  • Severe Renal Failure (Creatinine Clearance \<30ml/h)
  • Active Herpes zoster infection
  • Severe anemia (Hb\<9g/dl)
  • Lymphocyte count below 750/mcl
  • Neutrophil count below 1000/mcl
  • Platelet count below 50000/mcl
  • Pregnancy or Lactation
  • Inability to give informed consent (severe transitory or permanent mental impairment, incapacitation)

Key Trial Info

Start Date :

April 10 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 10 2020

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04332042

Start Date

April 10 2020

End Date

July 10 2020

Last Update

April 2 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ospedali Riuniti di Ancona

Ancona, The Marches, Italy, 60126

TOFAcitinib in SARS-CoV2 Pneumonia | DecenTrialz